NCT03971747Unknown1 期
A Phase 1 Study of AFP Specific T Cell Receptor Transduced T Cells Injection in Unresectable Hepatocellular Carcinoma
Shanghai AbelZeta Ltd.1 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2019年8月6日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Incidence of treatment related adverse events as assessed by CTCAE v4.0[Safety of C-TCR055]
研究概览
简要总结
A phase 1 study that aimed to assess the safety and anti-tumor activity of C-TCR055 injection in unresectable HCC patients.
详细描述
This study plans to enroll 9 patients to assess the safety of C-TCR055. Subjects who meet the eligibility criteria will receive a single dose of C-TCR055 injection, and will be followed up post treatment for safety monitoring. The follow up period will last 12 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to provide written informed consent.
- •Age 18-70 years old, male or female.
- •Patients must meet the following criteria:
- •Histologically confirmed HCC
- •Serum AFP >200 ng/mL
- •Child-Pugh score ≤6
- •BCLC stage B and stage C or stage Ⅱa/Ⅱb and Ⅲa/Ⅲb defined by Chinese Liver Cancer Guideline（2017）
- •Clinical confirmed relapse or progression if patient had locoregional therapy previously
- •Systemic therapy failed HCC Subject: those who received standardized systemic treatment for unresectable HCC and subsequently relapsed/progressed, or were intolerable or unwilling to receive treatment. Front-line system treatment should be approved in China (sorafenib, lenvastinib, platinum-containing chemotherapy regimen, regofinil)
- •. Local treatment (including surgery, ablation, interventional therapy, local radiotherapy, etc.) must be completed at least 4 weeks before apheresis, and there is no unhealed wound.
- •Previous systemic therapy was discontinued at least 2 weeks before apheresis.
- •Has at least 1 measurable lesion as defined per RECIST v1.
- •HLA-A 02:01 allele positive.
- •Liver AFP expression IHC tests:
- •≥20% tumor cells positive, and ≤5% non-tumor tissue positive;
- •serum AFP ≥400ng/ml, and ≤5% non-tumor tissue positive.
- •ECOG score ≤
- •Expected survival > 12 weeks
- •Left ventricular ejection fraction (LVEF) ≥ 50% (measured by echocardiography).
- •No active pulmonary infections, normal pulmonary function and oxygen saturation ≥ 92% on room air.
- •Laboratory criteria
- •Absolute neutrophil count (ANC) ≥ 1.5x10^9/ L
- •Platelets≥ 60x10^9/L
- •Hemoglobin≥ 90g/L
- •Serum total bilirubin ≤ 2 x ULN
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤5 x ULN
- •Creatinine ≤1.5×ULN
- •International normalized ratio (INR) or prothrombin time (PT) ≤1.5 x ULN
- •If patient has previous HBV infection, patient should receive antivirals treatment following treatment guidelines during study period, and the HBV DNA copies should below the detection limit at screening.
- •Female subjects in childbearing age, their serum or urine pregnancy test must be negative, all subjects must agree to take effective contraceptive measures during the trial.
- •Agree to abstain from alcohol during the study period
- •No contraindications for apheresis
- •Apheresis was received by laboratory ,and passed QC
排除标准
- •Have a history of allergy to cellular products.
- •Subject has liver transplantation history.
- •tumor volume was greater than 70% of liver tissue
- •main portal vein carcinoma thrombus
- •Medium to severe ascites.
- •subjects received other anti-tumor systemic therapy except standard systemic therapy. Or subjects received immunocheckpoint inhibitors was less than 6 weeks or 2 drug half-lives.
- •Subject has other primary cancer except for the following:
- •A. Non-melanoma cured by excision, such as basal cell skin cancer. B. Cured in situ cancers such as cervical cancer, bladder cancer or breast cancer
- •Significant clinical gastrointestinal bleeding within 4 weeks before treatment.
- •Subjects with bone metastasis or central nervous system metastasis, or with hepatic encephalopathy, epilepsy, cerebrovascular accident and other central nervous system involvement diseases.
- •Prior treatment with genetically modified T cell therapy or stem cell therapy.
- •Uncontrolled active infection. Preventive antibiotics, antiviral and antifungal are permitted.
- •Active hepatitis virus infection. HCV RNA positive.
- •Subjects with syphilis or other acquired, congenital immunodeficiency disorders, including, but not limited to, HIV infected persons, systemic lupus erythematosus, psoriasis, etc.
- •Heart insufficiency subjects of Grade III or IV according to NYHA classification criteria.
- •Subjects received systemic therapeutic steroid doses (except for the recent or current use of inhaled steroids) or other immunotherapy (such as interleukin-interferon, thymosin, etc.) within 2 weeks before Leukocyte apheresis.
- •Subjects received radiotherapy within 6weeks before Leukocyte apheresis
- •Subjects who are pregnant, lactating, or pregnant within 6 months
- •Any other disease that may increase the risk of the subject or interfere with the results of the study.
结局指标
主要结局
Incidence of treatment related adverse events as assessed by CTCAE v4.0[Safety of C-TCR055]
时间窗: start treatment to 12 months
Determine if treatment with C-TCR055 is safe through assessment of adverse events(AEs) and serious adverse events(SAEs) as assessed by CTCAE v4.0
次要结局
- PFS(12 months)
- OS(6 months and 12 months)
- ORR(3 months and 6 months)
- DOR(12 months)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaNCT04368182Zhejiang University3
招募中
1 期
Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid TumorsSolid TumorNCT03891706Guangzhou FineImmune Biotechnology Co., LTD.30
Unknown
1 期
TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver TransplantationRecurrent Hepatocellular CarcinomaNCT04677088Xiaoshun He7
终止
1 期
Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor CancersSolid TumorHER-2 Protein OverexpressionNCT03680560Cogent Biosciences, Inc.6
招募中
1 期
Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)Multiple MyelomaNCT06196255Xuzhou Medical University20